Astellas Pharma (ALPMF) Earnings Dates, Call Summary & Reports

58 Followers

Earnings Data

Report Date

Aug 05, 2026

TBA (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

0.31

Last Year’s EPS

0.24

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 6 Analysts Ratings

Earnings Call Summary

Q4 2024

Earnings Call Date:Apr 25, 2025|

% Change Since:

Earnings Call Sentiment|Positive

Astellas Pharma demonstrated strong financial performance with record-breaking revenue and significant growth in Strategic Brands. Successful cost optimization and a positive outlook for FY 2025, including increased dividends and progress in primary focus programs, highlight a positive trajectory. Despite challenges such as the impact of U.S. Medicare Part D redesign and temporary demand issues with IZERVAY, the overall sentiment remains optimistic.

Company Guidance

During the FY 2024 financial results announcement by Astellas Pharma Inc., several key financial metrics were highlighted, indicating a record year for the company. Revenue reached ¥1.912 trillion, marking a 19.2% increase year-on-year, while core operating profit rose by 41.7% to ¥392.4 billion. The company achieved significant growth in its Strategic Brands, with sales exceeding ¥340 billion, reflecting a growth of ¥180 billion or 110% year-on-year. The core operating profit margin improved by 3.3 percentage points to 20.5%. Astellas also reported substantial cost optimization, achieving a target of ¥40 billion, which improved the SG&A ratio by 3.1 percentage points. The Forex impact positively contributed ¥68.1 billion to revenue and ¥15.1 billion to core operating profit. Looking forward, Astellas forecasts further growth in FY 2025, with expected revenue of ¥1.930 trillion and a core operating profit increase to ¥410 billion, driven by continued expansion in Strategic Brands and ongoing cost optimization efforts.

Record-Breaking Revenue and Growth

In FY 2024, Astellas Pharma reported record high revenue of ¥1.912 trillion, a 19.2% increase year-on-year, and core operating profit of ¥392.4 billion, up by 41.7% year-on-year.

Strategic Brands Driving Growth

Sales of Strategic Brands, including PADCEV, IZERVAY, VEOZAH, VYLOY, and XOSPATA, exceeded ¥340 billion, more than doubling with a growth of ¥180 billion or 110% year-on-year.

Cost Optimization Success

Astellas Pharma achieved its cost optimization target of ¥40 billion in FY 2024, improving the SG&A ratio by 3.1 percentage points year-on-year.

Strong Outlook for FY 2025

Astellas expects continued strong momentum in Strategic Brands with projected revenue of ¥1.930 trillion and underlying growth excluding Forex impact expected to be 7%.

Dividend Increase

Astellas increased its dividend per share to ¥78, an increase of ¥4, in anticipation of future profit growth.

Primary Focus Program Progress

ASB-3082 achieved proof of concept (PoC) in pancreatic ductal adenocarcinoma, marking a significant milestone in targeted protein degradation.

Astellas Pharma (ALPMF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALPMF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2026	2026 (Q1)	0.31 / -	0.235	―	―	―
Apr 27, 2026	2025 (Q4)	0.19 / 0.15	0.257	-41.95% (-0.11)
Feb 04, 2026	2025 (Q3)	0.28 / 0.34	-0.336	202.73% (+0.68)
Oct 30, 2025	2025 (Q2)	0.18 / 0.27	0.123	120.44% (+0.15)
Jul 30, 2025	2025 (Q1)	0.12 / 0.24	0.129	82.00% (+0.11)
Apr 25, 2025	2024 (Q4)	0.13 / 0.26	-0.114	325.50% (+0.37)
Feb 04, 2025	2024 (Q3)	0.15 / -0.34	0.064	-624.52% (-0.40)
Oct 30, 2024	2024 (Q2)	0.11 / 0.12	-0.005	2607.50% (+0.13)
Aug 01, 2024	2024 (Q1)	0.06 / 0.13	0.114	13.76% (+0.02)
Apr 25, 2024	2023 (Q4)	-0.02 / -0.11	-0.155	26.34% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALPMF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 27, 2026	$15.60	$15.60	0.00%
Feb 04, 2026	$14.18	$14.68	+3.48%
Oct 30, 2025	$10.45	$10.90	+4.28%
Jul 30, 2025	$9.17	$10.06	+9.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Astellas Pharma Inc (ALPMF) report earnings?

Astellas Pharma Inc (ALPMF) is schdueled to report earning on Aug 05, 2026, TBA (Confirmed).

What is Astellas Pharma Inc (ALPMF) earnings time?

Astellas Pharma Inc (ALPMF) earnings time is at Aug 05, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALPMF EPS forecast?

ALPMF EPS forecast for the fiscal quarter 2026 (Q1) is 0.31.